The VEGF inhibitor vatalanib regulates AD pathology in 5xFAD mice.
Mol Brain
; 13(1): 131, 2020 09 25.
Article
en En
| MEDLINE
| ID: mdl-32977842
Alzheimer's disease (AD) is a highly prevalent neurodegenerative disease characterized by Aß accumulation and tau hyperphosphorylation. Epidemiological evidence for a negative correlation between cancer and AD has led to the proposed use of tyrosine kinase inhibitors (TKIs) such as dasatinib and masitinib for AD, with reported beneficial effects in the AD brain. The TKI vatalanib inhibits angiogenesis by inhibiting vascular endothelial growth factor receptor (VEGFR). Although changes in VEGF and VEGFR have been documented in AD, the effect of vatalanib on AD pathology has not been investigated. In this study, the effects of vatalanib on tau phosphorylation and Aß accumulation in 5xFAD mice, a model of AD, were evaluated by immunohistochemistry. Vatalanib administration significantly reduced tau phosphorylation at AT8 and AT100 by increasing p-GSK-3ß (Ser9) in 5xFAD mice. In addition, vatalanib reduced the number and area of Aß plaques in the cortex in 5xFAD mice. Our results suggest that vatalanib has potential as a regulator of AD pathology.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ftalazinas
/
Piridinas
/
Factor A de Crecimiento Endotelial Vascular
/
Enfermedad de Alzheimer
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Mol Brain
Asunto de la revista:
BIOLOGIA MOLECULAR
/
CEREBRO
Año:
2020
Tipo del documento:
Article
Pais de publicación:
Reino Unido